Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2009-09-09

FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for the pioglitazone and glimepiride fixed-dose combination submitted by Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pioglitazone and Glimepiride (pioglitazone and glimepiride)

Snippet

SUPPL AP for PIOGLITAZONE AND GLIMEPIRIDE (PIOGLITAZONE AND GLIMEPIRIDE)